Scaling a cGMP Cell Therapy Manufacturing Platform from Prototype to Clinical Production
From Design Transfer to First Shipment in 5 Months, Earning FDA Advanced Manufacturing Technology Designation A fast-growing cell therapy company needed to transition a fully integrated, cGMP-compliant CAR-T manufacturing platform from laboratory prototype to low-volume production in preparation for clinical trial deployment. Ascential assumed turn-key manufacturing responsibility and delivered the first completed instrument within 5 […]
Automation in Cell & Gene Therapy: Enabling Personalized Medicine at Scale
Automation in Cell & Gene Therapy: Enabling Personalized Medicine at Scale
Cell Therapy Manufacturing Services: Reducing Time to Market with Automation
As cell and gene therapies continue to revolutionize the healthcare landscape, manufacturers face a growing number of challenges in scaling production and bringing treatments to market efficiently. With patient-specific treatments and complex workflows, cell therapy manufacturing requires unparalleled precision, quality, and compliance. To overcome these hurdles, more companies are turning to cell therapy contract manufacturing […]
The Path to Production: Insights from the 2024 Bioprocessing Summit in Boston
Cell and gene therapies are rapidly transforming healthcare, offering promising new treatments for a range of serious conditions. However, scaling these therapies from early-stage development to commercial production presents significant challenges. At the recent Bioprocessing Summit in Boston, Todd Martensen, Chief Commercial Officer of Ascential Medical & Life Sciences, shared valuable insights with life sciences […]
Solving Quality Control Challenges in Cell Therapy Manufacturing
Overcoming the Bottleneck in Cell and Gene Therapy Manufacturing
The following is a synopsis of an article published in HIT Consultant. Click here to read the full article. Cell and gene therapies hold immense promise for treating cancer, autoimmune disorders, and other conditions by utilizing living cells to precisely target diseases. Despite rapid scientific advancements, manufacturing these therapies remains costly and slow, creating a […]
MD&M West 2024: Brace for a Medical Devices Value Chain Overhaul
